DDP 225

Drug Profile

DDP 225

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Mitsubishi Chemical
  • Developer Dynogen Pharmaceuticals
  • Class Analgesics; Antidepressants; Irritable bowel syndrome therapies; Nootropics; Pyrimidines; Small molecules; Urologics
  • Mechanism of Action Adrenergic receptor antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Irritable bowel syndrome; Major depressive disorder; Nausea and vomiting; Overactive bladder

Most Recent Events

  • 23 May 2008 Adverse events data from a Phase-IIa trial in Irritable bowel syndrome presented at the Digestive Disease Week 2008 (DDW-2008)
  • 17 Jan 2008 Patent rights and know-how relating to DDP 225 transferred from Arachnova Therapeutics to Dynogen Pharmaceuticals through an asset purchase agreement
  • 20 Dec 2007 Discontinued - Phase-II for Nausea and vomiting in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top